CIBC Private Wealth Group
NVCT icon

CIBC Private Wealth Group’s Nuvectis Pharma NVCT Stock Holding History

CIBC Private Wealth Group’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$110K Buy
+14,574
New +$95K ﹤0.01% 1464

Other funds holding NVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

CIBC Private Wealth Group's NVCT Position: Q4 2025 in Review

CIBC Private Wealth Group opened a new position in Nuvectis Pharma (NVCT) in Q4 2025: 14,574 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #1464 among its holdings.

48 funds tracked by Wall St. Rank hold NVCT as of Q4 2025.

  • CIBC Private Wealth Group held 14,574 shares of Nuvectis Pharma worth $110K as of Q4 2025.
  • Nuvectis Pharma was a new CIBC Private Wealth Group position in Q4 2025.
  • Nuvectis Pharma made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #1464 holding.
  • 48 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.